Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
Recruiting · NCT06760273 · Registry updated 2025-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II) | Bacterial Infections and Mycoses, Infections, Pseudomonas infection, bacterial infectious disease, bronchial disorder, bronchiectasis, gram-negative bacterial infections, respiratory system disorder | Recruiting | Not stated | 2025-04-01 | NCT06760273 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Pulmonary Hospital, Shanghai, China | 98 |
58 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.